Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 21,483 matching trials from the live ClinicalTrials.gov search.
Filters: Boston, Massachusetts Clear all
Completed Phase 3 Interventional Results available

Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia

NCT01753336
View directory record Official record
Conditions
Cervical Dystonia
Interventions
Botulinum toxin type A
Biological
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
41
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Nov 6, 2026, 2:32 PM EST
Completed Phase 1Phase 2 Interventional

Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer

NCT03888612
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
ARV-110
Drug
Lead sponsor
Arvinas Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
54
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 51 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Nov 6, 2026, 2:32 PM EST
Active, not recruiting Phase 2 Interventional

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

NCT02981628
View directory record Official record
Conditions
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma
Interventions
Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Diagnostic Imaging Testing, Inotuzumab Ozogamicin, Leucovorin Calcium, Lumbar Puncture, Methotrexate, Pegaspargase, Vincristine
Drug · Procedure · Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
156
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 127 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 6, 2026, 2:32 PM EST
Terminated Not applicable Interventional Accepts healthy volunteers

Pelvic Obliquity Rehabilitation in Stroke Patients Using Robotically Generated Force Fields

NCT01684267
View directory record Official record
Conditions
Gait Re-training in Healthy Subjects, Gait Re-training in Stroke Survivors
Interventions
Robotic Gait Rehabilitation (RGR) Trainer
Device
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
30 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Nov 6, 2026, 2:32 PM EST
Completed Phase 3 Interventional

A Study of Glaucoma or Ocular Hypertension in Patients Within the United States

NCT00800267
View directory record Official record
Conditions
Ocular Hypertension, Glaucoma
Interventions
latanoprost 0.005%, fixed combination latanoprost-timolol, timolol 0.5%
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1999
U.S. locations
53
States / cities
Anaheim, California • Sacramento, California • San Francisco, California + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Nov 6, 2026, 2:32 PM EST
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative Colitis

NCT00336492
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
infliximab
Biological
Lead sponsor
Centocor, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Nov 6, 2026, 2:32 PM EST
Active, not recruiting Phase 2 Interventional

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

NCT05482971
View directory record Official record
Conditions
Essential Thrombocythemia
Interventions
Ropeginterferon alfa-2b-njft (P1101)
Drug
Lead sponsor
PharmaEssentia
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
30
States / cities
Birmingham, Alabama • Duarte, California • Greenbrae, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Nov 6, 2026, 2:32 PM EST
Not listed Not applicable Interventional Accepts healthy volunteers

Aromatase Activity and Ovarian Growth Factors in African-American Versus Caucasian Women

NCT00334971
View directory record Official record
Conditions
Healthy, Fragile X Syndrome
Interventions
Follicle Aspiration
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Nov 6, 2026, 2:32 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults

NCT00528489
View directory record Official record
Conditions
HIV Infections
Interventions
PennVax B, IL-12, IL-15
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
8
States / cities
Birmingham, Alabama • San Francisco, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Nov 6, 2026, 2:32 PM EST
Completed Not applicable Interventional

Neurosurgical Use of Interstitial Laser Therapy (ILT)

NCT00207350
View directory record Official record
Conditions
Brain Tumor
Interventions
Interstitial Laser Therapy
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Nov 6, 2026, 2:32 PM EST
Completed Phase 2Phase 3 Interventional Results available

Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa

NCT00310791
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Hormone replacement therapy (estrogen/progestin), Placebo (Sugar Pill), Dehydroepiandrosterone (DHEA)
Drug · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
15 Years to 30 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Nov 6, 2026, 2:32 PM EST
Completed Phase 1 Interventional

A Study of the Safety and Pharmacokinetics (PK) of MEHD7945A in Participants With Locally Advanced or Metastatic Epithelial Tumors

NCT01207323
View directory record Official record
Conditions
Epithelial Tumors, Malignant
Interventions
MEHD7945A
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
3
States / cities
Aurora, Colorado • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Nov 6, 2026, 2:32 PM EST
Completed No phase listed Observational

Pyruvate Kinase Deficiency Natural History Study

NCT02053480
View directory record Official record
Conditions
Pyruvate Kinase Deficiency, Congenital Non-Spherocytic Hemolytic Anemia
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
19
States / cities
Phoenix, Arizona • Palo Alto, California • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated May 22, 2020 · Synced Nov 6, 2026, 2:32 PM EST
Completed Not applicable Interventional Results available

Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit

NCT03648762
View directory record Official record
Conditions
Heart Failure
Interventions
Aerobic Exercise Intervention, Combined Aerobic and Strength Exercise Intervention, Inspiratory Muscle Training Exercise Intervention
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Nov 6, 2026, 2:32 PM EST
Terminated Phase 3 Interventional Results available

Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)

NCT02718417
View directory record Official record
Conditions
Ovarian Cancer
Interventions
carboplatin, paclitaxel, Avelumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
998 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
146
States / cities
Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 70 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Nov 6, 2026, 2:32 PM EST
Completed Phase 2 Interventional

Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease

NCT00138840
View directory record Official record
Conditions
Crohn's Disease
Interventions
STA-5326 mesylate
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years to 75 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
31
States / cities
Little Rock, Arkansas • Anaheim, California • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2008 · Synced Nov 6, 2026, 2:32 PM EST
Recruiting Not applicable Interventional

Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease

NCT07613840
View directory record Official record
Conditions
Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis), Platelet Aggregation Inhibitors, Thromboelastography (TEG), PRU(Platelet Reactivity Unit)
Interventions
Aspirin, Clopidogrel, Ticagrelor, Rivaroxaban, Thromboelastography with Platelet Mapping
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Salem, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 6, 2026, 2:32 PM EST
Completed Phase 2 Interventional Results available

Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury

NCT04633889
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Deferoxamine, Normal saline
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 6, 2026, 2:32 PM EST
Active, not recruiting Not applicable Interventional

Evaluation of Safety and Effectiveness of Stryker Surpass Evolve™ Flow Diverter System

NCT04195568
View directory record Official record
Conditions
Aneurysm, Intracranial
Interventions
Surpass Evolve Flow Diverter System
Device
Lead sponsor
Stryker Neurovascular
Industry
Eligibility
18 Years to 80 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
32
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Nov 6, 2026, 2:32 PM EST
Terminated Phase 3 Interventional Results available

Zileuton to Treat Adults With Chronic Obstructive Pulmonary Disease (The LEUKO Study)

NCT00493974
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Zileuton, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
45 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Nov 6, 2026, 2:32 PM EST
Completed Phase 2 Interventional

An Open-Label Study of XOMA 358 in Patients With Hypoglycemia After Gastric Bypass Surgery

NCT02772718
View directory record Official record
Conditions
Hypoglycemia
Interventions
XOMA 358 single dose level A, XOMA 358 single dose level B, XOMA 358 single dose level C, XOMA 358 multiple dose level 1
Drug
Lead sponsor
XOMA (US) LLC
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
5
States / cities
Aurora, Colorado • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 21, 2021 · Synced Nov 6, 2026, 2:32 PM EST
Completed Phase 1 Interventional Results available

A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer

NCT00510718
View directory record Official record
Conditions
Prostate Cancer, Hormone Refractory Prostate Cancer
Interventions
MDV3100
Drug
Lead sponsor
Pfizer
Industry
Eligibility
Male only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
9
States / cities
Boston, Massachusetts • New York, New York • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Nov 6, 2026, 2:32 PM EST
Recruiting Not applicable Interventional

NeuroPathways Intervention for Brain Tumor Patients

NCT05976490
View directory record Official record
Conditions
Malignant Brain Tumor, Glioma, Coping Skills
Interventions
Information and Support Intervention, Usual supportive care
Behavioral · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Nov 6, 2026, 2:32 PM EST
Completed Phase 2 Interventional

Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

NCT01423110
View directory record Official record
Conditions
Sporadic Inclusion Body Myositis
Interventions
BYM338, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Scottsdale, Arizona • Kansas City, Kansas • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Nov 6, 2026, 2:32 PM EST